FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 790 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Getting Help for Sexual Health Problems When You Have Head and... April 14, 2022 Thinking outside the box to tackle an aggressive children’s cancer September 8, 2021 Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of... April 27, 2023 Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... August 14, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Selpercatinib Tough questions for tough times in clinical research New treatment for Waldenstrom’s macroglobulinaemia in England Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem
